The latest research study has unveiled that Type 2 diabetes patients with obstructive sleep apnea or OSA could be the victims of blindness within an average period of four years.
A recent study has unveiled that the drug canagliflozin plays important role in treating the type 2 diabetes and simultaneously reduces the risk of the kidney problem and heart disease.
Researchers from the University of Copenhagen, University of Colorado, Tufts University and two institutions presented data that showed the determining factor of weight loss in fasting plasma glucose.
The FDA has recently asked the pharmaceutical company, Johnson & Johnson, to add warnings to the diabetes drug Invokana about the risk of leg and the foot amputations.